Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation

NCT02264210 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT02264210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02264210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
July 31, 2022
Enrollment
128 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the lung, adenosquamous cell lung cancer, bronchial neoplasms, large cell lung cancer, lung neoplasms, squamous cell lung cancer, stage ib non-small cell lung cancer